Evaluation of the medical and economic performance of the French Plan for Genomic Medicine 2025 is being set up, in connection with health professionals, for the duration of the plan.
The introduction of economic calculations into political decisions should ensure that available resources are allocated in an optimal way.
The goal is to design a national economic model in a way that allows the population to benefit from progress in genomic medicine, while ensuring the sustainability of collective resources.
For such purposes, a research programme associated with the medico-economic aspects of implantation of genomic medicine in medical practice is implemented.
The sequencing platforms have been subject to continuous medico-economic studies since their launch.
Medico-economic studies are part of the objectives of the pilot projects in the plan, in particular the analysis of the social and financial impact.
In France, two legislative measures structure the economic calculations in the definition of the scope of reimbursable care:
- on the one hand, the health budget is voted each year by the Parliament in the framework of the Social Security Financing Act (LFSS);
- on the other hand, the criterion of effectiveness has been integrated in the decision to price health goods and services since October 2013.